 |
| |
|
BC00019
Multiple organ squamous cell carcinoma tissue array, 63 cases/63 cores
|
|
| Microarray Panel: | Multiple organ squamous cell carcinoma tissue microarray, single core per case with 63 cases of squamous cell carcinoma (bladder, breast, ear, esophagus, eye, gallbladder, gingiva, kidney, larynx, lip, lung, nasopharynx, nose, ovary, penis, pharynx, rectum, salivary gland, skin, stomach, thymus, tongue, ureter, uterus and vulva) |
| Cores: | 63 |
|
| Cases: | 63 |
| Layout: | 9 cols × 7 rows |
| Core Diameter: | 1.5 mm |
| Thickness: | 5 µm | | Quality Control: | Anti-Cytokeratin (CK) confirmed | | Applications: | Routine histology procedures including ImmunoHistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found on our support page. |
| Notes: | Unless specified, all TMA slides are not coated with extra layer of paraffin (tissue cores can be easily seen on the glass), so there is no need to bake, can be directly put into xylene for de-paraffin procedure. |
*Tissue Microarray Slide Types:
- Unstained: unstained
paraffin
tissue microarray slide.
- Trial: tissue microarray trial slide. 10% - 25% of cores missing. Good for titrating antibody dilution and experiment conditions. Limited numbers are available, to 2 per item per order. Test slides (tissue arrays with catalog numbers ending with 241 or 242) are recommended as a substitute.
- H & E: Hematoxylin and Eosin stained tissue microarray slide.
Microarray Panel Display | Legend: | Bla - Bladder,
Bre - Breast,
Ear - Ear,
Eso - Esophagus,
Eye - Eye,
Gal - Gallbladder,
Gin - Gingiva,
Kid - Kidney,
Lar - Larynx,
Lip - Lip,
Lun - Lung,
Nas - Nasopharynx,
Nos - Nose,
Ova - Ovary,
Pen - Penis,
Pha - Pharynx,
Rec - Rectum,
Sal - Salivary gland,
Ski - Skin,
Sto - Stomach,
Thy - Thymus,
Ton - Tongue,
Ure - Ureter,
Ute - Uterus,
Vul - Vulva
 - Malignant tumor
|
Specification Sheet
| Pos |
No. |
Sex |
Age |
Organ |
Pathology diagnosis |
Grade |
Type † |
|
A1 |
1 |
M |
37 |
Skin |
Squamous cell carcinoma |
I |
Malignant |
|
A2 |
2 |
M |
62 |
Esophagus |
Squamous cell carcinoma (sparse) |
III |
Malignant |
|
A3 |
3 |
M |
56 |
Larynx |
Squamous cell carcinoma |
I |
Malignant |
|
A4 |
4 |
M |
51 |
Lung |
Squamous cell carcinoma |
III |
Malignant |
|
A5 |
5 |
M |
36 |
Gingiva |
Squamous cell carcinoma |
I |
Malignant |
|
A6 |
6 |
M |
43 |
Penis |
Squamous cell carcinoma |
I |
Malignant |
|
A7 |
7 |
F |
49 |
Uterine cervix |
Squamous cell carcinoma |
II |
Malignant |
|
A8 |
8 |
F |
29 |
Vulva |
Squamous cell carcinoma |
I |
Malignant |
|
A9 |
9 |
M |
52 |
Stomach |
Squamous cell carcinoma |
III |
Malignant |
|
B1 |
10 |
M |
85 |
Skin |
Squamous cell carcinoma |
I |
Malignant |
|
B2 |
11 |
M |
66 |
Esophagus |
Squamous cell carcinoma |
II |
Malignant |
|
B3 |
12 |
M |
71 |
Larynx |
Squamous cell carcinoma |
II |
Malignant |
|
B4 |
13 |
M |
65 |
Lung |
Squamous cell carcinoma |
I |
Malignant |
|
B5 |
14 |
M |
55 |
Gingiva |
Squamous cell carcinoma |
III |
Malignant |
|
B6 |
15 |
M |
47 |
Penis |
Cancer adjacent tissue (chronic inflammation) |
– |
Malignant |
|
B7 |
16 |
F |
55 |
Uterine cervix |
Squamous cell carcinoma |
III |
Malignant |
|
B8 |
17 |
F |
42 |
Vulva |
Squamous cell carcinoma |
I |
Malignant |
|
B9 |
18 |
F |
68 |
Stomach |
Squamous cell carcinoma |
III |
Malignant |
|
C1 |
19 |
F |
78 |
Skin |
Squamous cell carcinoma |
III |
Malignant |
|
C2 |
20 |
F |
46 |
Esophagus |
Squamous cell carcinoma |
III |
Malignant |
|
C3 |
21 |
M |
62 |
Larynx |
Squamous cell carcinoma |
II |
Malignant |
|
C4 |
22 |
M |
73 |
Lung |
Squamous cell carcinoma |
I |
Malignant |
|
C5 |
23 |
M |
49 |
Tongue |
Squamous cell carcinoma |
II |
Malignant |
|
C6 |
24 |
M |
60 |
Penis |
Squamous cell carcinoma |
I |
Malignant |
|
C7 |
25 |
F |
56 |
Uterine cervix |
Squamous cell carcinoma |
I |
Malignant |
|
C8 |
26 |
F |
46 |
Vulva |
Squamous cell carcinoma |
I |
Malignant |
|
C9 |
27 |
M |
38 |
Stomach |
Squamous cell carcinoma |
II |
Malignant |
|
D1 |
28 |
F |
90 |
Skin |
Squamous cell carcinoma |
II |
Malignant |
|
D2 |
29 |
M |
66 |
Esophagus |
Squamous cell carcinoma |
I |
Malignant |
|
D3 |
30 |
M |
56 |
Larynx |
Squamous cell carcinoma |
III |
Malignant |
|
D4 |
31 |
M |
64 |
Lung |
Squamous cell carcinoma |
III |
Malignant |
|
D5 |
32 |
F |
52 |
Lip |
Squamous cell carcinoma |
II |
Malignant |
|
D6 |
33 |
M |
70 |
Penis |
Squamous cell carcinoma |
I |
Malignant |
|
D7 |
34 |
F |
46 |
Uterine cervix |
Squamous cell carcinoma |
II |
Malignant |
|
D8 |
35 |
F |
59 |
Vulva |
Squamous cell carcinoma |
II |
Malignant |
|
D9 |
36 |
M |
54 |
Stomach |
Squamous cell carcinoma |
III |
Malignant |
|
E1 |
37 |
F |
85 |
Skin |
Cancer adjacent tissue (with hyperplasia of epithelium) |
– |
Malignant |
|
E2 |
38 |
F |
47 |
Esophagus |
Squamous cell carcinoma |
II |
Malignant |
|
E3 |
39 |
M |
51 |
Larynx |
Squamous cell carcinoma |
I |
Malignant |
|
E4 |
40 |
M |
63 |
Lung |
Squamous cell carcinoma |
III |
Malignant |
|
E5 |
41 |
M |
81 |
Lip |
Squamous cell carcinoma |
I |
Malignant |
|
E6 |
42 |
M |
50 |
Penis |
Squamous cell carcinoma |
I |
Malignant |
|
E7 |
43 |
F |
40 |
Uterine cervix |
Squamous cell carcinoma |
II |
Malignant |
|
E8 |
44 |
F |
56 |
Vulva |
Squamous cell carcinoma |
I |
Malignant |
|
E9 |
45 |
F |
42 |
Stomach |
Squamous cell carcinoma |
III |
Malignant |
|
F1 |
46 |
M |
53 |
Kidney |
Squamous cell carcinoma |
I |
Malignant |
|
F2 |
47 |
F |
55 |
Uterus |
Squamous cell carcinoma |
III |
Malignant |
|
F3 |
48 |
F |
72 |
Ovary |
Squamous cell carcinoma |
III |
Malignant |
|
F4 |
49 |
F |
57 |
Tongue |
Squamous cell carcinoma |
I |
Malignant |
|
F5 |
50 |
M |
57 |
Lip |
Squamous cell carcinoma |
I |
Malignant |
|
F6 |
51 |
M |
49 |
Ear |
Squamous cell carcinoma (sparse) |
III |
Malignant |
|
F7 |
52 |
M |
78 |
Salivary gland |
Squamous cell carcinoma |
III |
Malignant |
|
F8 |
53 |
F |
47 |
Breast |
Squamous cell carcinoma |
III |
Malignant |
|
F9 |
54 |
F |
50 |
Thymus |
Squamous cell carcinoma |
III |
Malignant |
|
G1 |
55 |
F |
50 |
Rectum |
Squamous cell carcinoma |
III |
Malignant |
|
G2 |
56 |
M |
42 |
Gallbladder |
Squamous cell carcinoma with necrosis |
III |
Malignant |
|
G3 |
57 |
M |
74 |
Bladder |
Squamous cell carcinoma |
I |
Malignant |
|
G4 |
58 |
M |
50 |
Ureter |
Squamous cell carcinoma |
III |
Malignant |
|
G5 |
59 |
M |
56 |
Eye |
Squamous cell carcinoma |
III |
Malignant |
|
G6 |
60 |
M |
57 |
Pharynx |
Squamous cell carcinoma |
I |
Malignant |
|
G7 |
61 |
M |
52 |
Nasopharynx |
Squamous cell carcinoma |
III |
Malignant |
|
G8 |
62 |
M |
42 |
Nose |
Squamous cell carcinoma |
III |
Malignant |
|
G9 |
63 |
M |
47 |
Nose |
Cancer adjacent tissue (chronic inflammation with hyperplasia |
– |
Malignant |
† For precise diagnosis, refer to pathology description.
**The grade 1-3 (or I-III) in Pathology Diagnosis is equivalent to well-differentiated, moderately-differentiated or poorly differentiated, respectively, under microscope.
Grade 1 or well-differentiated: Cells appear normal and are not growing rapidly.
Grade 2 or moderately-differentiated: Cells appear slightly different than normal.
Grade 3 or poorly differentiated: Cells appear abnormal and tend to grow and spread more aggressively.
Grade 4 or undifferentiated: *(for certain tumors), features are not significantly distinguishing to make it look any different from undifferentiated cancers which occur in other organs.
|
|
